Recro Pharma Inc. (NASDAQ:REPH)’s share price was up 27.6% on Wednesday . The stock traded as high as $12.50 and last traded at $9.80, with a volume of 378,170 shares changing hands. The stock had previously closed at $7.68.

Several equities analysts have weighed in on REPH shares. Zacks Investment Research cut Recro Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, March 31st. Brean Capital reaffirmed a “buy” rating and set a $28.00 target price on shares of Recro Pharma in a research note on Friday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Recro Pharma in a research note on Monday, July 18th.

The stock’s market capitalization is $93.73 million. The stock’s 50 day moving average is $8.01 and its 200 day moving average is $7.20.

Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.05. The firm earned $17.70 million during the quarter, compared to analyst estimates of $13 million. Equities research analysts anticipate that Recro Pharma Inc. will post ($3.41) earnings per share for the current year.

In other Recro Pharma news, Director Winston J. Churchill sold 58,331 shares of the stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $7.91, for a total value of $461,398.21. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Scp Vitalife Partners (Israel) sold 6,260 shares of the stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $6.46, for a total value of $40,439.60. Following the completion of the transaction, the insider now directly owns 783,642 shares in the company, valued at approximately $5,062,327.32. The disclosure for this sale can be found here.

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.